Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19 patients: A real-world evidence study
Shambosamrat Samajdar, Shatavisa Mukherjee, Saibal Moitra, Jyotirmoy Pal, Shashank Joshi, Santanukumar Tripathi
Lung India, doi:10.4103/lungindia.lungindia_268_22
Background: Cough is a wearisome and exasperating symptom affecting the daily life of the infected patient. Cough due to coronavirus disease 2019 (COVID-19) causes excessive morbidity in human populations globally. Apart from the morbidity associated with cough, it also enhances the transmission of this viral infection through droplets. Therefore, curbing cough is crucial to limit its spread. Patients often administer over-the-counter products and antitussive agents, which have no proven benefit. The present study was undertaken to find out if cough associated with COVID-19 and other indicative clinical outcomes is alleviated with a budesonide/formoterol fixed-dose combination (FDC) metered-dose inhaler (MDI). Materials and Methods: A prospective observational study was conducted in mild COVID-19 patients who presented with a cough score ≥8 at presentation. Patients who were initiated on ICS-LABA MDI were observed as group A and those who were not initiated on MDI were observed as Group B. Cough symptom score (at baseline and on day 3 and day 7), the incidence of hospital admission and/or death, and need for mechanical ventilation were documented. Prescribing patterns of anti-cough medications were also noted and analysed. Results: Compared to group B, a higher mean cough score reduction was noted for group A patients at day 3 and day 7 when compared to the baseline, and this was significant at P < 0.001. A significant negative correlation was also observed between mean latency of MDI initiation from the symptom onset and mean cough score reduction. Analysis of the proportion of patients prescribed medications to treat cough showed that overall, 10.78% did not require these, with a greater proportion in group A compared to group B. Conclusion: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 who were treated with ICS-LABA MDI along with usual care benefitted significantly in terms of symptom reduction compared to usual care.
Ethical approval The study has been approved by the Ethics Committee vide letter no HREC-AARC/13.
Financial support and sponsorship
Nil.
Conflicts of interest There are no conflicts of interest.
References
Anderson, Formoterol: Pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator, Life Sci
Becker, Hom, Villasis-Keever, Der Wouden, Beta2-agonists for acute cough or a clinical diagnosis of acute bronchitis, Cochrane Database Syst Rev
Finney, Glanville, Farne, Aniscenko, Fenwick et al., Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon, J Allergy Clin Immunol
Footitt, Johnston, Cough and viruses in airways disease: Mechanisms, Pulm Pharmacol Ther
Freund-Michel, Birrell, Giembycz, Hele, Haj-Yahia et al., Beta(2)-agonists block tussive responses in pigs via an atypical cAMP-dependent pathway, Eur Respir J
Gibson, Saltos, Fakes, Acute anti-inflammatory effects of inhaled budesonide in asthma: A randomized controlled trial, Am J Respir Crit Care Med
Grant, Geoghegan, Arbyn, Mohammed, Mcguinness et al., The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries, PLoS One
Griesel, Wagner, Mikolajewska, Stegemann, Fichtner et al., Inhaled corticosteroids for the treatment of COVID-19, Cochrane Database Syst Rev
Hsu, Stone, Worsdell, Busst, Chung, Coughing frequency in patients with persistent cough: Assessment using a 24 hour ambulatory recorder, Eur Respir J
Jacoby, Virus-induced asthma attacks, JAMA
Jeon, Ko, Lee, Choi, Byun et al., Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs, Antimicrob Agents Chemother
Jintana, Prasertsopon, Puthavathana, Lerdsamran, Antiviral effect in association with anti-apoptosis and anti-autophagy of repurposing formoterol fumarate dihydrate on enterovirus A71-infected neuronal cells, Virus Res
Korn, Jerre, Brattsand, Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells, Eur Respir J
Lipworth, Kuo, Lipworth, Chan, Inhaled Corticosteroids and COVID-19, Am J Respir Crit Care Med
Mahmoudvand, Shokri, Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19, Scand J Immunol
Peters, Sajuthi, Deford, Christenson, Rios et al., NHLBI severe asthma research program-3 investigators. COVID-19-related genes in sputum cells in asthma: Relationship to demographic features and corticosteroids, Am J Respir Crit Care Med
Ramakrishnan, Nicolau, Jr, Langford, Mahdi et al., Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, andomized controlled trial, Lancet Respir Med
Sulaiman, Aljuhani, Aamer, Shaya, Shaya et al., The role of inhaled corticosteroids (ICS) in critically Ill patients with COVID-19: A multicenter, cohort study, J Intensive Care Med
Wallin, Sandstrom, Soderberg, Howarth, Lundbäck et al., The effects of regular inhaled formoterol, budesonide and placebo on mucosal inflammation and clinical indices in mild asthma, Am J Respir Crit Care Med
Yamaya, Nishimura, Deng, Sugawara, Watanabe et al., Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HcoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells, Respir Investig
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors formortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet
